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Abstract: Individuals with COPD have systemic inﬂ  ammation that can be assessed by 
measuring C-reactive protein (CRP). In this paper we evaluated whether CRP is related to 
COPD, lung function and rate of lung function decline.
We included 1237 randomly selected subjects (mean age 42, range 28–56 years) from three 
centers in the European Community Respiratory Health Survey: Reykjavik, Uppsala and Tartu. 
CRP was measured at the end of the follow-up (mean 8.3 years) and the values were divided 
into 4 quartiles.
Fifty-three non-asthmatic subjects fulﬁ  lled spirometric criteria for COPD (FEV1/FVC 
  70%). COPD occurred more often in the 4th CRP quartile (OR (95% CI) 3.21 (1.13–9.08)) 
after adjustment for age, gender, body weight and smoking. High CRP levels were related to 
lower FEV1 values in both men (−437 (−596, −279) mL) and women (−144 (−243, −44) mL). 
The negative association between CRP and FEV1 was signiﬁ  cantly larger in men than women 
(p = 0.04). The decline in FEV1 was larger (16 (5, 27) mL) in men with high CRP levels whereas 
no signiﬁ  cant association between CRP and FEV1 decline was found in women.
Higher CRP values are signiﬁ  cantly associated with COPD and lower lung function in men 
and women. In men higher CRP values are related to a larger decline in FEV1.
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Introduction
Chronic obstructive lung disease (COPD) is characterized by a progressive airﬂ  ow 
limitation and is associated with an abnormal inﬂ  ammatory process in the lungs 
(Pauwels et al 2001). COPD is a major cause of morbidity and disability (Murray and 
Lopez 1996). Forced expiratory volume in one second (FEV1) is a marker of COPD 
used in staging and evaluating prognosis of the disease and correlates with mortality 
and health status (Jones and Agusti 2006). Factors associated with decline in FEV1 
are of interest as they might have prognostic importance in COPD.
C-reactive protein (CRP) is a sensitive marker of inﬂ  ammation, infection and tissue 
damage which contributes to host defenses against infection by activating complement 
pathways (Pepys and Hirschﬁ  eld 2003). Highly sensitive assays for CRP are available 
and reﬂ  ect low grade inﬂ  ammation (Wilkins et al 1998).
Elevated levels of CRP have been reported in overweight adults (Visser et al 
1999; Danesh et al 2004). Adiposity and weight change have been associated 
with an unfavorable development in respiratory function (Burchﬁ  el et al 1996; 
Chinn et al 1996; Wang et al 1997). In a study estimating the effects of smoking 
and weight change a gender difference was reported where weight gain seems to 
diminish the beneﬁ  t of smoking cessation by 38% in men and by 17% in women 
(Chinn et al 2005).International Journal of COPD 2007:2(4) 636
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Studies have demonstrated elevated levels of CRP and 
ﬁ  brinogen in patients with COPD (Mannino et al 2003; 
Gan et al 2005) and a meta-analysis by Gan et al (2004) 
conﬁ  rmed a signiﬁ  cant increase in CRP levels in COPD 
patients compared with controls indicating a persistent 
systemic inﬂ  ammation in subjects with COPD. Donaldson 
et al (2005) examined 148 patients with moderate to severe 
COPD and showed that high levels of inﬂ  ammatory markers 
are associated with a faster decline in lung function.
Smoking is the major contributor to COPD and a fast 
decline in FEV1 (Anthonisen et al 2002). Numerous reports 
have shown current smokers to have higher CRP levels than 
non-smokers (Tamakoshi et al 2003; Danesh et al 2004; 
Gan et al 2005) and a positive association with the number 
of pack-years smoked (Frohlich et al 2003) but interestingly 
smoking and reduced lung function seem to have independent 
effects on CRP levels (Gan et al 2005).
The aim of this paper was to explore the relationship 
between CRP, smoking, COPD and lung function in a popula-
tion sample of young and middle aged adults from Iceland, 
Estonia and Sweden.
Methods
Population
The European community respiratory health survey (ECRHS) 
is an international multi-centre epidemiological study of 
asthma and allergy. The ﬁ  rst part, ECRHS I, was conducted 
in 1990–1994 and the follow-up study, ECRHS II, in 
1999–2001. The design of ECRHS I and ECRHS II has been 
published elsewhere (Burney et al 1994; Anon 2002).
The present study includes data from three of the 29 cen-
ters in the ECRHS II: Reykjavik in Iceland, Tartu in Estonia 
and Uppsala in Sweden – where 2033 subjects participated in 
stage 2 of ECRHS I (Ólafsdóttir et al 2005). The number of 
subjects in the present analysis was 1289 (age range 28–56 
years), of which 512 subjects were from Reykjavik, 288 
from Tartu and 489 from Uppsala (participation rate 63.4%). 
Mean time between ﬁ  rst (ECRHS I) and second spirometry 
(ECRHS II) was 8.3 ± 0.8 years. Only subjects with CRP 
measurement and an acceptable spirometry were included 
in the study (n = 1237).
Subjects were asked to postpone their examination if 
they had suffered from respiratory infection in the 3 weeks 
immediately preceding the examination, as this was a crite-
rion for exclusion. Written informed consent was obtained 
from each subject before inclusion in the study. The relevant 
ethics authorities in each of the participating research centers 
approved the protocol.
Smoking
A questionnaire administered on each occasion provided 
information on smoking history. Those who answered “yes” 
to the lead question (“Have you ever smoked for as long as 
a year?”) were asked “Do you smoke now, as of one month 
ago?” Those that answered yes to the ﬁ  rst question and no 
to the second were considered to be ex-smokers. Additional 
questions were asked on age at starting, amount smoked cur-
rently, whether they had stopped or cut down, and amount 
smoked previously. Based on this information the subjects 
were classiﬁ  ed into Never-smoker, Ex-smoker and Smok-
ers. Lifetime and between survey exposure to smoking was 
calculated as pack years (Chinn et al 2005).
Spirometry
In all three centers lung function was performed using the 
same spirometer in ECRHS I and II. The maximum FEV1 
and maximum forced vital capacity (FVC) of up to ﬁ  ve tech-
nically acceptable blows were determined, and also whether 
FEV1 and FVC each met the American Thoracic Society cri-
terion for reproducibility (Anon 1995). Decline in FEV1 and 
FVC was expressed per year of follow-up (ECRHS I value 
minus ECRHS II value) (Chinn, Jarvis et al 2005). Predicted 
values for forced expiratory volume in one second (FEV1) 
were calculated based on the European Coal and Steel Union 
reference values (Anon 1983).
Deﬁ  nition of COPD
The criterion for COPD in the present study was a FEV1/FVC 
  70% (Pauwels et al 2001; de Marco et al 2004). Subjects 
with an FEV/FVC   70% that reported usually having cough 
or bringing up phlegm at least three months each year were 
deﬁ  ned as being at risk for COPD (Global initiative for 
chronic obstructive lung disease (GOLD) stage 0) (Pauwels 
et al 2001; de Marco et al 2004). Subject with a self-reported 
history of physician’s diagnosed asthma were not considered 
as having COPD or GOLD stage 0.
Body mass index
BMI was calculated as weight in kilograms divided by the 
square of height in meters.
CRP measurements
CRP was measured at the end of the follow-up period. The 
analysis was carried out at the Dept. of Clinical Biochemistry, 
Landspitali University Hospital Iceland. All serum samples 
were stored frozen at –20 ºC. High sensitivity CRP concen-
trations were measured on a Hitachi 911 analyzer using a International Journal of COPD 2007:2(4) 637
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commercially available latex-enhanced immunoturbidimetric 
assay from Roche. The lower detection limit of the assay 
is 0.1 mg/L. Two internal control specimens provided by 
the reagent manufacturer were measured in each batch of 
samples. The total coefﬁ  cient of variation for CRP measure-
ments of the internal controls was 1.1% at a concentration of 
3.73 mg/L and 1.9% at a concentration of 0.68 mg/L.
Statistical analyses
Log-transformed values of CRP were used when analys-
ing the relationship between CRP and pack years and the 
association between CRP and FEV1 in subjects with COPD. 
The subjects were divided into four groups according to the 
quartile distribution of the CRP values ( 0.45, 0.46–0.96, 
0.97−2.21 and  2.21) when estimating risk association. Test 
for trend was used when analysing associations between 
CRP-quartiles and age, sex, smoking and BMI in the uni-
variate analyses. Odds ratios for the relationship between 
COPD and CRP were calculated using logistic regression 
while multiple linear regressions were used to examine the 
association between lung function and CRP. Analyses of 
sex interaction were performed. Analyses of the association 
between CRP and lung function was performed separately 
in men and women as a signiﬁ  cant sex interaction was found 
in the association between CRP and FEV1. The adjusted risk 
ratios and adjusted estimates of the linear regressions with a 
95% conﬁ  dence interval (CI) were ﬁ  rst analyzed on pooled 
data from all three centers, adjusting for centre and then 
calculated separately at each centre. Potential heterogeneity 
between centers was examined using standard methods for 
random-effects meta-analysis.
Results
The study population (n = 1237) included 595 men and 642 
women, mean age 42 (range 28–56) years, 29.7% ex-smokers 
and 26.4% current smokers. CRP values ranged from  0.1 
to 70.0 mg/L. Characteristics of the study population divided 
in CRP quartiles are presented in Table 1. There were no sig-
niﬁ  cant centre or gender differences in CRP levels, but there 
was a statistically signiﬁ  cant positive correlation between 
CRP and current smoking, pack years and BMI (Table 1). 
The positive association between the number of pack years 
smoked and CRP was found in both ex- and current smok-
ers (Figure 1).
CRP and COPD
Fifty-three participants (4.2%, 25 men and 28 women) 
fulﬁ  lled the criteria for having COPD and additionally 
87 (7.0%) were deﬁ  ned as being at risk for COPD (GOLD 
stage 0). Eleven subjects had GOLD stage II or more. The 
lowest prevalence of subjects fulﬁ  lling the criteria for COPD 
was in those with the lowest CRP values and remained sig-
niﬁ  cant after adjusting for centre, age, sex, BMI and pack 
years (Table 2). There was no signiﬁ  cant relation between 
CRP and GOLD stage 0. There was a correlation between 
COPD severity expressed as FEV1 as % of the predicted and 
CRP in the 53 subjects with COPD (Figure 2). No signiﬁ  cant 
gender interaction (p = 0.91) or centre heterogeneity was 
found in the associations between CRP and COPD (p for 
heterogeneity = 0.31).
CRP and lung function
Men and women with CRP values above 0.46 mg/L had 
signiﬁ  cantly lower FEV1 and FVC values than subjects with 
CRP values within the ﬁ  rst quartile (Table 3, Figure 3). The 
negative association between CRP and FEV1 was signiﬁ  cantly 
larger in men than women (p = 0.04), whereas no gender 
difference in the association between CRP and FVC was 
found (Figure 3). The mean annual decline in FEV1 was 44 
mL in men and 31mL in women. Men with higher CRP values 
than 0.46 mg/L had a signiﬁ  cantly larger decline in FEV1 
while no signiﬁ  cant association between CRP and decline 
in lung function was found in women (Table 4). Decline in 
FEV1, when not adjusted for CRP, was also signiﬁ  cantly 
related to elevated BMI in both men and women and to 
the intensity of smoking between the surveys in women 
(Table 4). In men the association between change in BMI and 
FEV1 decline increased when not adjusting for CRP [13 (6, 
21) mL/year for each 5 unit increase in BMI, (adjusted effect 
(95% CI)], while no similar effect was found in women.
No significant interaction was found between CRP, 
smoking and change in body mass index in relation to lung 
function and decline in FEV1. No centre heterogeneity was 
found in the associations between CRP and lung function 
with one exception. A signiﬁ  cantly larger decline in FEV1 
was found in women with the highest CRP values in Uppsala 
[15 (6–24) mL/year] (p for heterogeneity = 0.002). No such 
association was found in the other centres.
Non-participants
Subjects that participated in both surveys (n = 1289) were 
slightly older (33.7 ± 7.2 vs 32.1 ± 7.0 years), had a higher 
BMI (23.9 ± 4.0 vs 23.3 ± 3.7 kg/m2) (p   0.0001) and were 
less often smokers (32.4 vs 37.0, p = 0.03) in the ECRHS 
I than the subjects that only participated in the ﬁ  rst survey 
(n = 744).International Journal of COPD 2007:2(4) 638
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Discussion
This study focuses on a well-deﬁ  ned general population. It 
demonstrates a strong association between elevated CRP 
levels and the prevalence of COPD and lower lung function 
(FVC and FEV1). The negative association between CRP and 
FEV1 was stronger in men than women and an association 
between faster decline of FEV1 and higher CRP levels was 
found in men but not women.
Our results are in accordance with a cross sectional study 
from the Third National Health and Nutrition Survey where 
CRP levels, independent of smoking, were found to be 
related to reduced FEV1 (Gan et al 2005). Broekhuizen et al 
(2006) showed that in 102 clinically stable COPD patients, 48 
had elevated CRP levels ( 4.21 mg/l) and these high levels 
where strongly associated with impaired energy metabolism 
and distress due to respiratory symptoms. A comparison of 
88 COPD patients with 33 smokers and 38 non-smokers 
controls, showed higher levels of CRP in COPD patients 
(Pinto-Plata et al 2006). In assessing the association between 
CRP and lung function Shaaban et al (2006) looked at cross-
sectional and longitudinal changes between CRP and FEV1 
decline. Their analysis included 531 subjects demonstrating 
a negative association between FEV1 and CRP (p = 0.002) 
and higher CRP levels over time were associated with a 
faster FEV1 decline. Similarly a recent study found CRP 
levels associated with accelerated decline in FEV1 and 
mortality in patients with mild to moderate COPD indicat-
ing that CRP measurements might enable identiﬁ  cation of 
patients at a high risk of disease progression and mortality 
(Man et al 2006).
Table 1 Characteristics of the study population in relation to CRP values
CRP  1st quartile:  2nd quartile:   3rd quartile:   4th quartile:   P for trend
(mg/L) <0.46  0.46–0.96  0.97–2.21  >2.21
Age (years)  40.5   7.0  42.5   7.2  42.6   7.2  42.6   7.4  0.0002
Women (%)  54.7  51.6  43.2  57.7  0.96
Ex-smokers (%)  28.6  30.8  24.8  34.0  0.38
Current smokers (%)  23.3  24.6  27.4  31.1  0.02
Pack years  5.0   7.7  8.2   13.3  9.1   13.5  12.6   16.6   0.0001
BMI (kg/m2) 23.3    2.9  24.9   3.5  26.3   4.0  27.9   5.2   0.0001
0.1
1
10
0.1 1 10 100 0.1 1 10 100
Pack years
r = 0.22, p = 0.0001 r = 0.25, p < 0.0001
CRP
(mg/L) Ex-smokers Smokers
Figure 1 Correlation between pack years and CRP in ex- and current smokers.International Journal of COPD 2007:2(4) 639
CRP and COPD
The present study underscores the link between systemic 
inﬂ  ammation and COPD. Many of prior studies have been 
focused on hospitalized subjects or COPD patients with 
severe COPD (GOLD III or IV). Our study implies that 
systemic inﬂ  ammation is a factor even in the early phase 
of the COPD process. The exact role of inﬂ  ammation in 
the pathogenesis of COPD is not fully understood. Lower 
airway bacterial colonization (Wilkinson et al 2003) and 
possibly upper airway bacterial inﬂ  ammation (Hurst et al 
2005) might provoke a systemic inﬂ  ammatory response in 
COPD patients. Elevated levels of inﬂ  ammatory markers 
such as plasma ﬁ  brinogen have been associated with reduced 
FEV1, accelerated decline in lung function and increased 
risk of COPD hospitalizations in the future (relative risk 1.7 
(95% CI: 1.1–2.6)) (Dahl et al 2001). A prospective study by 
Wilkinson et al (2003) including 30 patients with moderate 
COPD over 12 months, showed that FEV1 decline was related 
to an increase in airway bacterial load (r = 0.59, p = 0.001) 
and higher sputum Il–8 was associated with greater declines 
in FEV1 (p = 0.03). However, CRP was not reported in these 
studies. Faster decline in FEV1 has also been associated with 
more frequent exacerbations of COPD (Donaldson et al 2002) 
Table 2 Prevalence of GOLD stage 0 and COPD and the independent association to CRP
  Stage 0  Stage 1+
CRP Prevalence  OR*  Prevalence  OR*
(mg/L)  (%)  (95% CI)  (%)  (95% CI)*
1st quartile:  0.46 6.9  1  2.2  1
2nd quartile: 0.46–0.96  5.5  0.78 (0.38–1.59)  5.2  2.90 (1.09–7.73)
3rd quartile: 0.97–2.21  6.9  0.95 (0.48–1.94)  3.9  1.94 (0.67–5.66)
4th quartile:  2.21 8.6  1.19  (0.59–2.39)  5.7  3.21  (1.13–9.08)
* The values are adjusted for centre, age, height, BMI and pack years.
40
60
80
100
120
140
CRP (mg/L)
0.1 0.3 1 3 10 30
FEV1 (% pred)
r = 0.45, p = 0.0008
Figure 2 Correlation between CRP values and FEV1 expressed as % of the predicted in subjects with COPD (n = 53).International Journal of COPD 2007:2(4) 640
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and a recent publication suggested that the chronic deterio-
ration in FEV1 decline is explained by the acute events in 
COPD causing a faster rate of rise in airway inﬂ  ammation 
(Donaldson et al 2005).
In our study men with higher CRP values had signiﬁ  cantly 
larger decline in FEV1 than men with low CRP whereas no 
such association was found in women. In an epidemiologi-
cal follow-up study like ours the fast rate of lung function 
decline and the diagnosis of COPD are strongly interrelated 
and in other studies it has usually been described as one 
of the deleterious consequences of smoking (Lange et al 
1989; Townsend et al 1991; Xu et al 1994; Burchﬁ  el et al 
1995). Chinn et al studied the effects of smoking cessation 
and weight gain on lung function in 6654 subjects. They 
showed gender differences with a signiﬁ  cantly faster rate of 
lung function decline in relation to weight gain in men than 
women (Chinn et al 2005).
We found that the association between weight change 
and FEV1 decline decreased when adjusting for CRP in men. 
This might indicate that weight-related effect on change in 
FEV1 could partly be mediated through increased systemic 
inﬂ  ammation. The strong relationship between increased 
body fat and lower lung function raises the question whether 
elevated CRP reﬂ  ects inﬂ  ammatory processes in the airways 
that overﬂ  ow into the systemic circulation, promoting a gen-
eralized inﬂ  ammatory reaction (Gan et al 2004). However in 
a recent review Wouters (2005) concluded that the inﬂ  amma-
tory process in the airways and the systemic circulation were 
two independent processes. It is also possible that smoking 
induces CRP elevation, as a signiﬁ  cant relationship was found 
between number of pack years and CRP levels in both ex- and 
current smokers in the present study. Alternatively elevated 
CRP may reﬂ  ect a genetic or constitutional factor predispos-
ing individuals with COPD to both systemic and pulmonary 
inﬂ  ammation (Barnes 2000; Hersh et al 2006).
Previously we published that CRP in the same study 
population is increased in non-allergic but not allergic asthma 
(Ólafsdóttir et al 2005). In this report COPD was signiﬁ  cantly 
more common in subjects with higher CRP quartiles. Despite 
adjustments for centre, age, sex, body mass index and pack 
years, a positive correlation was found between the severity 
of COPD (FEV1%) and CRP values. The relatively young 
age of our study population (mean age 42, range 28–56 years) 
is of great clinical importance, as they have not yet reached 
the age with repeated hospitalizations due to exacerbations 
of COPD but do show rapid lung function decline.
The strengths of this study include the use of data from a 
general population, gathered and assessed with high quality 
and standardized methods as part of the ECRHS. The limita-
tions merit some discussion. Firstly CRP was only measured 
at the end of our study while FEV1 was measured at two 
time points and our assumptions on FEV1 decline are based 
on these measurements. However, CRP levels measured at 
multiple time points have been stable in many studies (Macy 
et al 1997; Ockene et al 2001; Ridker et al 2005). Secondly 
we found that the participants were less likely to be smok-
ers and slightly more obese than the non-participants. We 
cannot rule out selection bias but do not believe that those 
limitations undermine our work.
The present study indicates that subjects with elevated 
CRP levels are at greater risk of having COPD and impaired 
lung function. A signiﬁ  cant gender difference was found 
where men with higher CRP values had a more rapid decline 
in FEV1 during the study period. Future studies will reveal 
whether lowering elevated levels of CRP in COPD patients 
with drugs such as statins (Ridker et al 2005) or inhaled 
corticosteroids in high doses (Sin et al 2004) will slow the 
clinical progress of the main outcome variables in COPD, 
namely, decline in lung function, number of exacerbations, 
health related quality of life and mortality. Treatment of a 
younger population like the one we studied is of particular 
interest as at their age lung function is rapidly decreasing 
but loss of health related quality of life is not yet an irre-
versible fact.
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 Men  Women
  mL/year (95% CI)  mL/year (95% CI)
CRP
2nd quartile: 0.46–0.96  10.7 (0.5, 20.8)  4.8 (–4.9, 12.6)
3rd quartile: 0.97–2.21  11.0 (1.1, 20.9)  1.4 (–7.0, 9.9)
4th quartile: >2.21  15.9 (4.6, 27.1)  –1.1 (–9.5, 7.3)
BMI at base line*  2.5 (–2.9, 7.8)  3.6 (–0.1, 7.3)
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